Innovations Advanced by M&A: The First Therapy for Pompe Disease

by Hanna | May 1, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in our series, Innovations Advanced by M&A, which underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...

House Committee on Small Business Urges FTC, DOJ to Consider Consequences of Recent Merger Guidelines on Early-Stage Companies

by Hanna | Apr 25, 2024 | Blog Post

Bipartisan policymakers continue to raise concerns about the recently finalized 2023 Merger Guidelines and their impact on early-stage companies. Last week, the House Committee on Small Business wrote to the Federal Trade Commission (FTC) and Antitrust Division of the...

‘Material Differences’ & ‘Less Burden’: FTC, DOJ Signal Forthcoming Changes to Proposed HSR Rules

by Hanna | Apr 24, 2024 | Blog Post

Speaking to antitrust experts at the ABA’s 2024 Spring Antitrust Meeting, Andrew Forman, deputy assistant attorney general at the Department of Justice’s (DOJ) Antitrust division, suggested that the Federal Trade Commission (FTC) and DOJ’s forthcoming changes to the...

Innovations Advanced by M&A: A Cure for Inherited Blindness

by Hanna | Apr 18, 2024 | Blog Post, Innovations Advanced by M&A

This blog is the first installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. Across the United States’ world-class life...

FTC & DOJ Focus on ‘Nascent Competition’ Ignores Unique Market Dynamics in the Life Sciences

by Hanna | Apr 10, 2024 | Blog Post

The Federal Trade Commission (FTC) and Department of Justice (DOJ) have increasingly focused on the impact that mergers and acquisitions (M&A) in the life sciences could have on “nascent competition” – the competition that might eventually exist between...

ITIF Report Finds Balanced Competition Policies Critical to Preserve U.S. Leadership in Biopharmaceutical Innovation

by Hanna | Mar 27, 2024 | Blog Post

In its recent report “Not Again: Why the United States Can’t Afford to Lose its Biopharma Industry,” the Information Technology & Innovation Foundation (ITIF) highlights the important role of balanced competition policies in establishing and maintaining U.S....

A Timeline of the FTC & DOJ’s Flawed Approach to Life Sciences M&A

by Hanna | Mar 11, 2024 | Blog Post

In recent years, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have taken an increasingly aggressive approach towards life sciences mergers and acquisitions (M&A). This new approach not only represents a substantial pivot away from the...

On Capitol Hill, PULSE Partners Highlight Unique Importance of Life Sciences M&A

by Hanna | Mar 7, 2024 | Blog Post

On February 29, PULSE partners from across the country met with policymakers on Capitol Hill to provide a real-world perspective on the critical role of pro-innovation mergers and acquisitions (M&A) and other collaborations in the life sciences industry. PULSE’s...

Overreach in M&A Enforcement: The Impact on Pro-Innovation Deals That Aren’t Ever Pursued

by Hanna | Feb 21, 2024 | Blog Post

In recent months, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have pursued an increasingly aggressive new approach towards mergers and acquisitions (M&A). Taken together, the Agencies’ recently finalized Merger Guidelines and proposed...

ICYMI – Law360: How Biotech Deals May Help Competition, Despite FTC View

by Hanna | Feb 13, 2024 | Blog Post

In a recent commentary for Law 360, biopharma expert Michael Kinch and economists Jee-Yonn Lehmann and Frederico Mantovanelli rightly point out that biopharmaceutical mergers and acquisitions (M&A) and other collaborations play an important role in promoting...